Skip to main
Telehealth Wolverine

THE QUESTION REGISTER

BPC-157 TB-500 FAQ: The Wolverine Blend, Answered

Twenty-five questions on the BPC-157 TB-500 blend, each answered directly and cited where the answer makes a quantitative claim.

Read the researchRegulatory status

Mechanism and definition

The BPC-157 TB-500 blend raises the same questions again and again: what each peptide is, how each works, and whether they truly act together. The answers below are grouped by theme and drawn from the published record.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500 is the synthetic Ac-LKKTETQ heptapeptide spanning the actin-binding region (residues 17–23) of thymosin beta-4; the LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration [3]. Structural crystallography of a thymosin beta-4–actin complex established the dual-end-capping sequestration mechanism [3].

How does BPC-157 work compared to TB-500?

They act through largely non-overlapping pathways: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation, growth-hormone-receptor sensitization of tendon fibroblasts) [2], while TB-500 / thymosin beta-4 supplies an intracellular actin-sequestration signal that regulates cell migration [3]. This complementarity is the basis of the blend's synergy claim, which is theoretical rather than demonstrated [9].

Do BPC-157 and TB-500 act through the same pathway?

No. BPC-157 acts mainly on the VEGFR2-Akt-eNOS angiogenic/cytoprotective axis and the growth-hormone-receptor/FAK-paxillin pathway in tendon fibroblasts [2]; TB-500 / thymosin beta-4 acts intracellularly by sequestering G-actin to regulate cytoskeletal remodeling and migration [3]. The pairing is rationalized as complementary, not identical, mechanisms.

What does TB-500 stand for and how does it relate to Thymosin Beta-4?

TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17–23 — the actin-binding motif — of the 43-residue intracellular protein thymosin beta-4 [3][7]. It is a fragment, not the whole protein; importantly, most efficacy data attributed to "TB-500" were generated with full-length thymosin beta-4 [11].

What is the Wolverine peptide blend?

Wolverine is a research-community name for a two-peptide tissue-repair pairing of BPC-157 with TB-500, discussed as a recovery stack [11]. It is not a single chemical entity, has no CAS number or molecular weight of its own, and is not an approved product.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein, studied for cytoprotection and angiogenesis [1][2]. TB-500 is the synthetic Ac-LKKTETQ fragment of thymosin beta-4, studied for actin-regulated cell migration [3]. The Wolverine blend pairs the two.

What is the BPC-157 and TB-500 blend used for in research?

In animal models the constituents are studied for tendon, ligament, muscle, and wound repair, angiogenesis, and cytoprotection [1][4]. The blend itself has no controlled combination study; the recovery rationale is extrapolated from each peptide's separate preclinical record [9].

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The pairing is rationalized as complementary mechanisms — BPC-157's local angiogenic/cytoprotective signal plus TB-500's cytoskeletal-migration signal — so the two are proposed to support tissue repair through different, non-overlapping routes [2][3]. No controlled combination study has defined a synergistic dose, ratio, or endpoint [9].

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid gastric-derived pentadecapeptide acting on VEGFR2-Akt-eNOS angiogenesis and tendon-fibroblast signaling; TB-500 is a 7-amino-acid Ac-LKKTETQ fragment of thymosin beta-4 acting by sequestering G-actin to regulate cell migration [2][3]. Different size, origin, and mechanism — paired for complementary repair signals.

Evidence and efficacy

These questions ask what the studies actually establish — and, repeatedly, the answer is that the evidence is single-compound and preclinical, never a combination trial.

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed combination study defines a synergy ratio, dose, or endpoint for the two given together [9]. A 2025 systematic review of BPC-157 (36 studies, only 1 human, no clinical safety data) makes no mention of TB-500 or combination use [10]; the synergy claim is a theoretical extrapolation.

Are there human clinical trials on the BPC-157 + TB-500 combination?

There are no controlled clinical trials of the combination for any indication [9]. Human data exist only for the individual constituents and are thin: three small BPC-157 pilot studies, and human safety/PK data for full-length thymosin beta-4 rather than the TB-500 seven-amino-acid fragment [11].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In animal models, BPC-157 accelerated healing of transected rat Achilles tendon across biomechanical and microscopic measures [1], and thymosin beta-4 acted as a chemoattractant for myoblasts in muscle injury [6]. These are single-compound rodent findings; no blend trial has tested tendon or ligament outcomes in humans [9].

Does BPC-157 and TB-500 help muscle tears and recovery?

Muscle-injury-induced thymosin beta-4 recruits myoblasts to injured muscle in mouse and myoblast models [6], and BPC-157 has rodent muscle- and tendon-repair data [1]. The recovery narrative rests on preclinical, single-compound evidence; the combination has no human efficacy data [9].

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

In research models, yes, by distinct routes: BPC-157 up-regulates VEGFR2 with downstream Akt-eNOS signaling and improved blood-flow recovery in ischemic muscle [2], while thymosin beta-4 promotes endothelial migration and angiogenesis [4]. This shared vascular thread is part of the blend's combination rationale.

Does the BPC-157 TB-500 blend help wound healing?

Thymosin beta-4 accelerated re-epithelialization, contraction, collagen deposition, and angiogenesis in rodent full-thickness wound models, alongside BPC-157's multi-tissue cytoprotection data [1][4]. These are single-compound animal findings; the blend has no controlled wound-healing trial [9].

Dosage, pharmacokinetics, and handling

Dosing questions about the blend run into the same wall: there is no validated human dose, frequency, or cycle for the combination. The answers describe what was studied in animals and how research material is handled, never a protocol.

What is the half-life of BPC-157 and TB-500?

No validated human PK half-life exists for either constituent at research doses, and none for the blend [14]. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog PK study; human full-length thymosin beta-4 showed dose-proportional PK, but no half-life is established for the TB-500 heptapeptide [11][14].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [11]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, and no validated reconstitution protocol exists for the blend.

How often should you inject BPC-157 and TB-500?

There is no validated dosing frequency for the blend in humans [9]. Community "loading then maintenance" protocols and fixed-ratio vials (for example 10 mg + 10 mg) have no controlled-trial basis [11]. Research routes (SC/IM/IP) are described for the constituents in animal studies only.

How do you cycle BPC-157 and TB-500?

No validated cycling schedule exists for the blend [9]. Community loading/maintenance cycles have no controlled-trial basis, and a rat embolic-stroke study found thymosin beta-4 dosing non-monotonic (a high 18 mg/kg dose gave no benefit), undermining "more is better" loading rationales [14].

Safety

Safety questions about the blend inherit the uncertainty of two unapproved peptides with thin human data — and one specific preclinical signal worth naming directly.

What are the side effects of BPC-157 and TB-500?

Human safety data are limited: BPC-157 has only small pilot studies, and the TB-500 seven-amino-acid fragment has no completed controlled human trials [11]. A theoretical tumor/angiogenesis concern attaches to thymosin beta-4's pro-migratory, pro-angiogenic activity [4]. Combining two unapproved peptides doubles the uncertainty; long-term human safety is unknown.

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 has been implicated in tumor metastasis and angiogenesis in cancer-model literature; the same pro-migratory and pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a safety signal from preclinical models, not a demonstrated clinical effect of the blend.